SlidesetHIVEuropean HIV Clinical Forum 2017Serum cystatine as a marker for estimated glomerular filtration rate (eGFR) assessment in HIV-1-infected patients with dolutegravir-based antiretroviral therapy (ART).- R. PalichView Slideset
SlidesetHIVEuropean HIV Clinical Forum 2017Genetic variability of HIV-2 LTR regions impacts transcriptional activities.- Q. Le HingratView Slideset
SlidesetHIVEuropean HIV Clinical Forum 2017In-vitro selection of resistance mutations to dolutegravir outside HIV-1 integrase.- Dr. Olivier DelelisView Slideset
SlidesetHIVEuropean HIV Clinical Forum 2017Clinical case presentation- Christina Mussini, MDView Slideset
SlidesetHIVEuropean HIV Clinical Forum 2017French national survey of resistance to integrase inhibitors in a context of routine hospital care (ANRS AC11 Virology Network).- A.G. MarcelinView Slideset
SlidesetHIVEuropean HIV Clinical Forum 2017Dolutegravir used in real-life provides high rates of virological response in conjunction with a rare emergence of integrase resistance.- D. ArmeniaView Slideset
SlidesetHIVEuropean HIV Clinical Forum 2017Real Life Experience of Dolutegravir and Lamivudine Dual Therapy as a Switching Regimen in HIV-TR Cohort.- D. Yağcı-ÇağlayıkView Slideset
DCDavid CooperMD, DScSlidesetHIVEuropean HIV Clinical Forum 2017What is the clinical support for reduced drug regimens?- David Cooper, MD, DScView Slideset
AMAnne-Geneviève MarcelinMDSlidesetHIVEuropean HIV Clinical Forum 2017What is the virological support for reduced drug regimens?- Anne-Geneviève Marcelin, MDView Slideset
CBCharles BoucherMD, PhDSlidesetHIVEuropean HIV Clinical Forum 2017State of the ART: Integrase Inhibitors Resistance- Charles Boucher, MD, PhDView Slideset
SlidesetHIVInternational Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2017Effect of high-risk sexual behaviouron diversity of the vaginal microbiota and abundance of lactobacillus- Jocelyn WesselsView Slideset
SlidesetHIVInternational Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2017Modulation of gut microbiota by indoleamine 2,3-dioxygenase 1 inhibitor during antiretroviral suppressed SIV infection in rhesus macaques- Zhang WangView Slideset
